Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Keros Therapeutics ( (KROS) ) has issued an announcement.
On June 6, 2025, Keros Therapeutics announced that its Chair and CEO, Jasbir Seehra, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025. This participation highlights Keros’ engagement with the healthcare investment community and may impact its visibility and industry positioning.
The most recent analyst rating on (KROS) stock is a Buy with a $100.00 price target. To see the full list of analyst forecasts on Keros Therapeutics stock, see the KROS Stock Forecast page.
Spark’s Take on KROS Stock
According to Spark, TipRanks’ AI Analyst, KROS is a Neutral.
The overall stock score of 50.9 reflects significant financial challenges, including unprofitability and reliance on external financing, balanced by strong technical momentum. The recent negative corporate event involving workforce reduction indicates strategic realignment but also potential instability. Valuation remains challenging due to negative earnings.
To see Spark’s full report on KROS stock, click here.
More about Keros Therapeutics
Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for disorders linked to dysfunctional signaling of the TGF-ß family of proteins. The company is a leader in understanding the role of these proteins, which regulate the growth, repair, and maintenance of various tissues. Keros’ lead product candidate, KER-065, targets neuromuscular diseases, while elritercept (KER-050) is aimed at treating cytopenias in patients with myelodysplastic syndrome and myelofibrosis.
Average Trading Volume: 962,925
Technical Sentiment Signal: Sell
Current Market Cap: $601.9M
For a thorough assessment of KROS stock, go to TipRanks’ Stock Analysis page.